BMC Cancer

SEP 8, 2026 · JOURNAL ARTICLE

Time to benefit of perioperative immunotherapy among patients with resectable non-small-cell lung cancer

BMC Cancer

Rigorous meta-analysis of 8 RCTs with reconstructed individual patient data and quantitative time-to-benefit modelling provides robust evidence on treatment duration, though findings are primarily analytical rather than from a new primary trial.

SEP 8, 2026 · JOURNAL ARTICLE

Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy

BMC Cancer

A prospective case–control study of modest size (150 participants) with clear separation between groups and strong ROC performance for a candidate biomarker, but surrogate endpoints (AUC, survival association) rather than a clinical trial of intervention, requiring confirmation in independent cohorts.

SEP 7, 2026 · JOURNAL ARTICLE

Structural classification of EGFR mutations and its association with TKI efficacy against compound and co-mutations in a Chinese NSCLC cohort: a single-center retrospective analysis

BMC Cancer

A single-center retrospective cohort study with clear findings on EGFR mutation subtypes and TKI sensitivity in a defined population, but limited by retrospective design, lack of survival or clinical outcome detail, and modest sample sizes for the key comparison groups.

SEP 4, 2026 · JOURNAL ARTICLE

PANoptosis-related HLTF promotes prostate cancer progression and serves as a potential therapeutic target

BMC Cancer

Early-stage mechanistic study combining bioinformatics clustering, cell-line experiments, and computational docking without clinical validation or in vivo efficacy data for proposed HLTF-targeting interventions.

SEP 4, 2026 · JOURNAL ARTICLE

Clinical outcomes of SMARCA4-deficient thoracic tumor patients and therapeutic value of immune checkpoint inhibitors in advanced stage patients

BMC Cancer

Single-centre retrospective cohort with small advanced-stage subgroups (n=16 per arm) and exploratory analyses; unadjusted PFS benefit for ICIs did not survive adjustment, and authors explicitly state findings are hypothesis-generating rather than confirmatory.

AUG 18, 2026 · JOURNAL ARTICLE

A clinico-radiomic nomogram for preoperative prediction of guideline-defined indications for postoperative adjuvant therapy in early-stage cervical cancer

BMC Cancer

A well-designed retrospective validation study of a diagnostic nomogram with good discrimination (AUC 0.865 in validation), but modest incremental gain over clinical variables alone and modest sample size requiring external confirmation.

AUG 15, 2026 · JOURNAL ARTICLE

Prognostic value of tissue-based DNA methylation biomarkers in non-small cell lung cancer: a systematic review

BMC Cancer

Systematic review of 20 studies confirming that tissue-based DNA methylation is frequently associated with worse survival in NSCLC, but methodological heterogeneity and lack of meta-analysis prevent definitive clinical recommendations.

AUG 15, 2026 · JOURNAL ARTICLE

From overweight/obesity to metabolic syndrome: increased postoperative survival risk in gastric cancer

BMC Cancer

A single-centre retrospective cohort study with propensity-score matching showing MetS combined with overweight/obesity associates with worse overall survival in gastric cancer, but the MetS-alone increment over overweight/obesity alone was not statistically significant and the study is underpowered for a definitive practice recommendation.